Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Guggenheim lowered its price target on Structure Therapeutics (NASDAQ:GPCR) to $90.00 from $92.00 on Thursday, while maintaining a Buy rating on the stock. According to InvestingPro data, the stock has seen significant pressure recently, with its RSI indicating oversold territory after falling substantially over the past three months.
The firm noted that Structure Therapeutics reaffirmed in its second-quarter 2025 earnings update that top-line data from the Phase 2b ACCESS and ACCESS II studies for its oral small molecule GLP1RA aleniglipron remains on track for a year-end 2025 readout.
Structure Therapeutics has expanded the follow-up period for both studies, including an open-label extension for ACCESS I and an 8-week extension for ACCESS II that will provide additional exposure at the higher 180 mg and 240 mg doses.
The company is launching three new studies to assess maintenance switching, body composition, and usage in Type 2 diabetes patients, all dosing at the higher 180 mg and 240 mg levels, with these studies designed to support aleniglipron competitiveness and Phase 3 readiness.
Structure Therapeutics also confirmed that its DACRA-based ACCG-2671 remains on track to enter clinical trials by year-end 2025, and the company still expects to announce a second development candidate before the end of the year.
In other recent news, Structure Therapeutics has been the focus of several analyst updates. JMP Securities adjusted its price target for the company to $87, down from $89, while maintaining a Market Outperform rating. The firm anticipates potential positive movement in Structure Therapeutics’ shares following Eli Lilly (NYSE:LLY)’s presentation of Phase 3 data for orforglipron at an upcoming conference. Clear Street initiated coverage on Structure Therapeutics with a Buy rating and a price target of $61, citing the company’s role in the oral drug revolution for the diabesity market. Cantor Fitzgerald reiterated its Overweight rating and $65 price target, pointing to recent trial data from Eli Lilly that could have implications for Structure’s own compound, aleniglipron. H.C. Wainwright also maintained its Buy rating with a $75 price target, following promising data from the ACHIEVE-1 trial on oral GLP-1 receptor agonists. JMP Securities continues to hold a Market Outperform rating, emphasizing the importance of upcoming Phase 2b data for aleniglipron expected by the end of 2025. These developments highlight the ongoing interest and analysis surrounding Structure Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.